Immunotherapy: a way to improve the therapeutic outcome of photodynamic therapy?
暂无分享,去创建一个
[1] N. Yamamoto,et al. Retracted: Immunotherapy of metastatic breast cancer patients with vitamin D‐binding protein‐derived macrophage activating factor (GcMAF) , 2008, International journal of cancer.
[2] M. Olivo,et al. Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins , 2007, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.
[3] Barbara W Henderson,et al. Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. , 2007, Cancer research.
[4] K. Chester,et al. Targeted photodynamic therapy with multiply‐loaded recombinant antibody fragments , 2007, International journal of cancer.
[5] M. Korbelik,et al. Photodynamic therapy-generated vaccines: relevance of tumour cell death expression , 2007, British Journal of Cancer.
[6] M. Chopp,et al. Combination Therapy with Antiangiogenic Treatment and Photodynamic Therapy for the Nude Mouse Bearing U87 Glioblastoma , 2007, Photochemistry and photobiology.
[7] A. Dalgleish,et al. Cell based cancer vaccines: regulatory and commercial development. , 2007, Vaccine.
[8] N. Berinstein. Enhancing cancer vaccines with immunomodulators. , 2007, Vaccine.
[9] Emilio Fernández-Varón,et al. Granulocyte and granulocyte macrophage colony-stimulating factors as therapy in human and veterinary medicine. , 2007, Veterinary journal.
[10] R. Johnson,et al. Hypoxia: A key regulator of angiogenesis in cancer , 2007, Cancer and Metastasis Reviews.
[11] Zheng Huang,et al. Combination of immunotherapy and photodynamic therapy in the treatment of Bowenoid papulosis. , 2007, Photodiagnosis and photodynamic therapy.
[12] Mark W. Dewhirst,et al. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment , 2007, Cancer and Metastasis Reviews.
[13] R. Boyle,et al. Development and characterization of novel photosensitizer : scFv conjugates for use in photodynamic therapy of cancer , 2007, Immunology.
[14] B. Baguley,et al. Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial , 2007, Cancer Chemotherapy and Pharmacology.
[15] A. Kunamneni,et al. Streptokinase—the drug of choice for thrombolytic therapy , 2007, Journal of Thrombosis and Thrombolysis.
[16] M. Korbelik,et al. Potentiation of photodynamic therapy of cancer by complement: the effect of γ-inulin , 2006, British Journal of Cancer.
[17] E. Mazzon,et al. Protective effect of Hypericum perforatum in zymosan-induced multiple organ dysfunction syndrome: relationship to its inhibitory effect on nitric oxide production and its peroxynitrite scavenging activity. , 2006, Nitric oxide : biology and chemistry.
[18] Mladen Korbelik,et al. Photodynamic therapy-generated vaccine for cancer therapy , 2006, Cancer Immunology, Immunotherapy.
[19] Michael R Hamblin,et al. Photodynamic therapy and anti-tumour immunity , 2006, Nature Reviews Cancer.
[20] H. Kato,et al. Systemic Antitumor Effect of Intratumoral Injection of Dendritic Cells in Combination with Local Photodynamic Therapy , 2006, Clinical Cancer Research.
[21] D. Nowis,et al. The influence of photodynamic therapy on the immune response. , 2005, Photodiagnosis and photodynamic therapy.
[22] B. Pogue,et al. Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. , 2005, Journal of the National Cancer Institute.
[23] P Jack Hoopes,et al. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates. , 2005, Cancer research.
[24] M. Olivo,et al. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models , 2005, Cancer Chemotherapy and Pharmacology.
[25] J. Vance,et al. Metabolism and functions of phosphatidylserine. , 2005, Progress in lipid research.
[26] Mark D. Savellano,et al. Photochemical Targeting of Epidermal Growth Factor Receptor: A Mechanistic Study , 2005, Clinical Cancer Research.
[27] Carlo Riccardo Rossi,et al. Tumor necrosis factor, cancer and anticancer therapy. , 2005, Cytokine & growth factor reviews.
[28] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[29] Simone Mocellin,et al. Part I: Vaccines for solid tumours. , 2004, The Lancet. Oncology.
[30] M. Adamek,et al. Combined treatment of urinary bladder cancer with the use of photodynamic therapy (PDT) and subsequent BCG-therapy: a pilot study. , 2004, Photodiagnosis and photodynamic therapy.
[31] S. Müller,et al. Current and new strategies in immunotherapy for superficial bladder cancer. , 2004, Urology.
[32] Mladen Korbelik,et al. Adjuvant treatment for complement activation increases the effectiveness of photodynamic therapy of solid tumors , 2004, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.
[33] A. Giaccia,et al. Hypoxic gene expression and metastasis , 2004, Cancer and Metastasis Reviews.
[34] P. Mróz,et al. Effective Photoimmunotherapy of Murine Colon Carcinoma Induced by the Combination of Photodynamic Therapy and Dendritic Cells , 2004, Clinical Cancer Research.
[35] D. Klinman. Immunotherapeutic uses of CpG oligodeoxynucleotides , 2004, Nature Reviews Immunology.
[36] K. Schroder,et al. Interferon- : an overview of signals, mechanisms and functions , 2004 .
[37] W. Greco,et al. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors. , 2003, Cancer research.
[38] O. Finn,et al. Cancer vaccines: between the idea and the reality , 2003, Nature Reviews Immunology.
[39] B W Henderson,et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation , 2003, British Journal of Cancer.
[40] Mark D. Savellano,et al. Targeting Cells That Overexpress the Epidermal Growth Factor Receptor with Polyethylene Glycolated BPD Verteporfin Photosensitizer Immunoconjugates¶ , 2003, Photochemistry and photobiology.
[41] T. Inokuchi,et al. Hyperthermic photodynamic therapy combined with topical administration of OK-432 in the mouse carcinoma. , 2003, Oral oncology.
[42] G. Dougan,et al. Live bacteria as the basis for immunotherapies against cancer , 2002, Expert review of vaccines.
[43] M. Korbelik,et al. Neutrophils as inflammatory and immune effectors in photodynamic therapy-treated mouse SCCVII tumours , 2002, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.
[44] D. Gillatt,et al. Use of bacille Calmette-Guérin in superficial bladder cancer , 2002, Postgraduate medical journal.
[45] Barbara W Henderson,et al. Generation of effective antitumor vaccines using photodynamic therapy. , 2002, Cancer research.
[46] M. Korbelik,et al. Induction of Systemic Neutrophil Response in Mice by Photodynamic Therapy of Solid Tumors¶ , 2001, Photochemistry and photobiology.
[47] T. Wilt,et al. A systematic review of intravesical bacillus Calmette‐Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer , 2001, BJU international.
[48] M. Korbelik,et al. Cancer treatment by photodynamic therapy combined with adoptive immunotherapy using genetically altered natural killer cell line , 2001, International journal of cancer.
[49] Michael R Hamblin,et al. Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo. , 2001, Cancer research.
[50] M. Korbelik,et al. Interaction Between Photodynamic Therapy and BCG Immunotherapy Responsible for the Reduced Recurrence of Treated Mouse Tumors ¶ , 2001, Photochemistry and photobiology.
[51] M. Korbelik,et al. Interaction Between Photodynamic Therapy and BCG Immunotherapy Responsible for the Reduced Recurrence of Treated Mouse Tumors¶ , 2001 .
[52] H. Oppelaar,et al. Targeting of aluminum (III) phthalocyanine tetrasulfonate by use of internalizing monoclonal antibodies: improved efficacy in photodynamic therapy. , 2001, Cancer research.
[53] G. Chrousos,et al. The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system. , 2000, Pharmacological reviews.
[54] K. Sano,et al. Enhancement of the photodynamic antitumor effect by streptococcal preparation OK-432 in the mouse carcinoma , 2000, Cancer Immunology, Immunotherapy.
[55] Michael R Hamblin,et al. Experimental photoimmunotherapy of hepatic metastases of colorectal cancer with a 17.1A chlorin(e6) immunoconjugate. , 2000, Cancer research.
[56] C J Gomer,et al. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. , 2000, Cancer research.
[57] D. Sauder,et al. Immunomodulatory and pharmacologic properties of imiquimod. , 2000, Journal of the American Academy of Dermatology.
[58] A. Dabrowska,et al. Potentiation of the anti-tumour effects of Photofrin®-based photodynamic therapy by localized treatment with G-CSF , 2000, British Journal of Cancer.
[59] J. Sedgwick,et al. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. , 1999, Cancer research.
[60] M. Korbelik,et al. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. , 1999, Cancer research.
[61] H. Oppelaar,et al. Development of meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for photoimmunotherapy. , 1999, Cancer research.
[62] B. Baguley,et al. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. , 1999, Cancer research.
[63] M. Korbelik,et al. Enhancement of tumour response to photodynamic therapy by adjuvant mycobacterium cell-wall treatment. , 1998, Journal of photochemistry and photobiology. B, Biology.
[64] N. J. Brown,et al. The influence of hypoxia and pH on aminolaevulinic acid-induced photodynamic therapy in bladder cancer cells in vitro. , 1998, British Journal of Cancer.
[65] W. Sluiter,et al. Role of interleukin 1 and granulocyte colony-stimulating factor in photofrin-based photodynamic therapy of rat rhabdomyosarcoma tumors. , 1997, Cancer research.
[66] T. Hasan,et al. Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model. , 1996, British Journal of Cancer.
[67] S. Krege,et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. , 1996, The Journal of urology.
[68] J. Krosl,et al. Potentiation of photodynamic therapy-elicited antitumor response by localized treatment with granulocyte-macrophage colony-stimulating factor. , 1996, Cancer research.
[69] H. S. de Bruijn,et al. Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. , 1996, Cancer research.
[70] M. Korbelik,et al. Potentiation of photodynamic therapy by immunotherapy: the effect of schizophyllan (SPG). , 1994, Cancer letters.
[71] J. Levy,et al. Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. , 1983, Journal of immunology.
[72] M. Korbelik. Photodynamic therapy-generated cancer vaccines. , 2010, Methods in molecular biology.
[73] Jeffrey W. Clark,et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.
[74] C. Gomer,et al. Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model. , 2006, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.
[75] Hong Liu,et al. Enhancement of Laser Cancer Treatment by a Chitosan-derived Immunoadjuvant¶ , 2005, Photochemistry and photobiology.
[76] D. Nowis,et al. Light and Light Sources for Pdt Direct Tumor Damage Mechanisms of Photodynamic Therapy , 2005 .
[77] R. D'Amato,et al. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. , 2003, Neoplasia.
[78] P. Kuppen,et al. The immunological consequences of photodynamic treatment of cancer, a literature review. , 2003, Immunobiology.
[79] M. Korbelik,et al. Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. , 1997, British Journal of Cancer.
[80] D. Bellnier. Potentiation of photodynamic therapy in mice with recombinant human tumor necrosis factor-alpha. , 1991, Journal of photochemistry and photobiology. B, Biology.
[81] D. Bellnier. Potentiation of photodynamic therapy in mice with recombinant human tumor necrosis factors-α , 1991 .